Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive
clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …

The immunosuppression and immune escape of current immunotherapy result in low
efficacy, and ferroptosis is greatly restricted by the low reactive oxygen species (ROS) …

Tissue localization is a critical determinant of T cell immunity. CD8+ T cells are contact-
dependent killers, which requires them to physically be within the tissue of interest to kill …